GNRHR and LHCGR (AA 1-29), (N-Term) antibody

Catalog No. ABIN6937329

The Mouse Monoclonal anti-GNRHR and LHCGR antibody is suitable to detect GNRHR and LHCGR in samples from Human and Rat. It has been validated for FACS, IF, IHC and WB.

Quick Overview for GNRHR and LHCGR (AA 1-29), (N-Term) antibody (ABIN6937329)

Target: GNRHR and LHCGR

Reactivity: Human, Rat

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)

Clone: F1G4

Product Details

Binding Specificity: AA 1-29, N-Term

Purpose: GnRH-Receptor / LH-RH Receptor Antibody

Specificity: Recognizes an epitope on the extracellular domain of gonadotropin releasing hormone (GnRH) receptor or luteinizing hormone receptor (LHCGR). Lutropin (also designated luteinizing hormone) plays a role in spermatogenesis and ovulation by stimulating the testes and ovaries to produce steroids. Gonadotropin (also designated choriogonadotropin) production in the placenta maintains estrogen and progesterone levels during the first trimester of pregnancy. Ovaries and testes abundantly express luteinizing hormone/choriogonadotropin receptor. GnRH receptor contains seven hydrophobic transmembrane domains connected by hydrophilic extracellular and intracellular loops characteristic of G-protein coupled receptors. GnRH stimulates the gonadotrophs of the anterior pituitary to secrete luteinizing hormone (LH) as well as follicle-stimulating hormone (FSH). GnRH influences the protective effect of pregnancy and Gonadotropin against breast cancer. The expression of GnRH on breast carcinoma correlates in part to the degree of tumor differentiation. GnRH-positive breast tumors occur more frequently in tumors with greater cell differentiation in premenopausal women. GnRH is present in luteal and granulosa cells as well as in ovarian cell membrane preparations.

Cross-Reactivity (Details): Human. Rat. Predicted to react with Pig, Rabbit.

Purification: 200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G.

Immunogen: A synthetic peptide aa 1-29 (MANSASPEQNQHCSAINNSIPLMQGNLPY) from the N-terminal of human GnRH receptor.

Isotype: IgG1, kappa

Application Details

Application Notes:

Known_Application: Flow Cytometry (1-2 μg/million cells), Immunofluorescence (1-2 μg/mL), Western Blot (1-2 μg/mL), Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues requires heating tissue sections in 1 mM EDTA, pH 8.0, for 45 min at 95°C followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.

Positive_Control: MCF-7, MDA231, T47D cells. Pituitary gland, ovarian or breast cancers.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: Prepared in 10  mM PBS

Preservative: Azide free

Storage: -20 °C,-80 °C

Storage Comment: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Expiry Date: 24 months

Target Details

Target: GNRHR and LHCGR

Background:

GnRH receptor, GnRH-R, GNRHR1, gonadotropin-releasing hormone (type 1) receptor 1, GRHR, HH7, leutinizing-releasing hormone receptor, LHRHR, LRHR, luliberin receptor, luteinizing hormone releasing hormone receptor, Type I GnRH receptor

MCF-7, MDA231, ovarian or breast cancers., T47D cells. Pituitary gland

Molecular Weight: 54-60kDa

Gene ID: 2798, 3973, 407587468490

UniProt: P30968